Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Study of DE-114A Ophthalmic Solution in Allergic Conjunctivitis
jRCT2080223566Phase 3Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of epinastine in allergic conjunctivitis (AC), sponsored by Santen Pharmaceutical. Primary endpoint: Long-term safety of DE-114A ophthalmic solution over 8 weeks. Started Jun 2017; status: completed.
02
Drugs
epinastine
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on jRCT2080223566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223566.